We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+19.58%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$161M
AUM Growth
+$20.9M
(+15%)
Cap. Flow
-$8.51M
Cap. Flow
% of AUM
-5.29%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
14
Avg Time Held
5.6
quarters
Top 10 Avg Time Held
4.7
quarters
Top 20 Avg Time Held
5.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$4.07M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$3.08M |
| 3 |
Cymabay Therapeutics
CBAY
|
+$2.81M |
| 4 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.01M |
| 5 |
Tvardi Therapeutics
TVRD
|
+$1.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$3.22M |
| 2 |
SPNC
Spectranetics Corp
SPNC
|
+$2.15M |
| 3 |
SANGAMO THERAPEUTICS INC
SGMO
|
+$1.98M |
| 4 |
Cellectis
CLLS
|
+$1.97M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$1.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.71% |
| 2 | Miscellaneous | 9.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $24.1M | 14.99% |
262,121
-41,500
| -14% | -$3.22M |
2015 Q2
9 quarters
|
|
2
AtriCure
ATRC
$2.89B
| $8.59M | 5.34% |
384,145
| – | – |
2013 Q2
17 quarters
|
|
3
BeOne Medicines Ltd
ONC
$39.5B
| $7.43M | 4.62% |
71,849
-1,187
| -2% | -$88.5K |
2016 Q1
6 quarters
|
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $6.44M | 4% |
460,451
-177,249
| -28% | -$1.77M |
2016 Q2
5 quarters
|
|
|
5
BioCryst Pharmaceuticals
BCRX
$2.06B
| $6.25M | 3.88% |
1,193,228
+602,100
| +102% | +$3.08M |
2016 Q4
3 quarters
|
|
|
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
| $5.96M | 3.7% |
216,119
| – | – |
2013 Q2
17 quarters
|
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $5.67M | 3.52% |
116,770
+10,000
| +9% | +$546K |
2014 Q3
12 quarters
|
|
8
DELISTED
Blueprint Medicines
BPMC
| $5.29M | 3.29% |
76,000
-6,000
| -7% | -$321K |
2016 Q4
3 quarters
|
|
|
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
| $4.24M | 2.63% |
346,013
+125,000
| +57% | +$1.3M |
2015 Q3
8 quarters
|
|
|
10
DELISTED
Cymabay Therapeutics
CBAY
| $3.51M | 2.18% |
435,000
+415,933
| +2,181% | +$2.81M |
2017 Q1
2 quarters
|
|
11
Neurocrine Biosciences
NBIX
$13.7B
| $3.34M | 2.07% |
54,508
| – | – |
2016 Q1
6 quarters
|
|
|
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.23M | 2% |
718,272
+451,772
| +170% | +$2.01M |
2014 Q3
12 quarters
|
|
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $3.22M | 2% |
31,609
-7,000
| -18% | -$612K |
2015 Q3
8 quarters
|
|
14
Insulet
PODD
$9.58B
| $3.17M | 1.97% |
57,484
-6,000
| -9% | -$328K |
2013 Q2
17 quarters
|
|
15
iShares Biotechnology ETF
IBB
$10.2B
| $2.9M | 1.8% |
26,100
| – | – |
2016 Q4
3 quarters
|
|
16
MacroGenics
MGNX
$218M
| $2.85M | 1.77% |
154,200
+35,000
| +29% | +$606K |
2015 Q3
8 quarters
|
|
|
17
DexCom
DXCM
$32.1B
| $2.81M | 1.75% |
+230,000
| New | +$4.07M |
2017 Q3
0 quarters
|
|
18
Akebia Therapeutics
AKBA
$213M
| $2.67M | 1.66% |
135,738
| – | – |
2017 Q1
2 quarters
|
|
19
Ascendis Pharma A/S
ASND
$14.7B
| $2.62M | 1.63% |
72,226
+39,012
| +117% | +$1.12M |
2015 Q1
10 quarters
|
|
20
Voyager Therapeutics
VYGR
$132M
| $2.41M | 1.5% |
117,259
-87,549
| -43% | -$988K |
2017 Q1
2 quarters
|
|
21
DELISTED
Radius Health, Inc.
RDUS
| $2.06M | 1.28% |
53,309
| – | – |
2016 Q1
6 quarters
|
|
22
DELISTED
Dermira, Inc.
DERM
| $2.04M | 1.27% |
75,500
| – | – |
2016 Q1
6 quarters
|
|
|
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
| $1.84M | 1.14% |
52,500
-3,309
| -6% | -$44.9K |
2015 Q1
10 quarters
|
|
24
Ardelyx
ARDX
$806M
| $1.82M | 1.13% |
325,409
-48,000
| -13% | -$253K |
2016 Q1
6 quarters
|
|
25
Spyre Therapeutics
SYRE
$7.52B
| $1.72M | 1.07% |
13,984
| – | – |
2016 Q2
5 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, DAFNA Capital Management held 88 positions worth $161M, up 15% from $140M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
DAFNA Capital Management withdrew a net $8.51M in Q3 2017, closing 14 positions and reducing 19 holdings. Its most notable exit was Spectranetics Corp, an estimated $2.15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in DexCom worth $2.81M.
- DAFNA Capital Management's largest Q3 2017 buy was DexCom: 230,000 shares worth $2.81M.
- DAFNA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $3.08M increase.
- DAFNA Capital Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $3.22M.
- DAFNA Capital Management fully exited Spectranetics Corp in Q3 2017, selling an estimated $2.15M.
- DAFNA Capital Management's ten largest holdings make up 48% of its $161M portfolio in Q3 2017.
- DAFNA Capital Management opened 12 new positions and closed 14 in Q3 2017.
- DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $161M.
Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.